Business
Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks
RA'ANANA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies,” “Inspira,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic commercial showcase of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system. The system will be featured at the American Society of Extracorporeal Technology (AmSECT) 64th International Conference, taking place Marc
About this update from Qtrex Quantum Ltd.
[{"type":"image","alt":"Inspira Technologies","displaySize":"","headline":null,"caption":"Inspira Technologies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Fe6OoV8FaU0yBPMg3F6WQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878","width":300,"height":71}},"lazy":false},{"type":"text","content":"RA'ANANA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies,” “Inspira,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic commercial showcase of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system. The system will be featured at the American Society of Extracorporeal Technology (AmSECT) 64th International Conference, taking place March 25–29, 2026, in Austin, Texas, at the exhibition booth of its U.S. distributor, Glo-Med Networks Inc. (“Glo-Med”).","length":620,"tagName":"p"},{"type":"text","content":"Key Commercial Highlights:","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Targeting Clinical Decision Makers: The ART100 will be positioned at AmSECT, the premier global venue for perfusionists and cardiac surgical teams who directly influence hospital purchasing decisions.","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"Leveraging FDA Clearance: The showcase capitalizes on the ART100’s FDA 510(k) clearance (received in May 2024) to validate the system’s readiness for immediate clinical integration in cardiopulmonary bypass procedures.","length":218,"tagName":"p"}]},{"val":[{"type":"text","content":"Active Distribution Channel: The presentation via Glo-Med demonstrates an active commercial pipeline, moving beyond development into sales execution and market visibility.","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":589,"olType":false},{"type":"text","content":"“We are moving fast to translate our FDA clearance into market share. Presenting the ART100 alongside Glo-Med at AmSECT allows us to engage directly with the decision-makers who drive hospital purchasing,” s...